Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 6-Month, Double-Blind, Phase 2 Study and 6-Month Open- Label Extension Evaluating the Safety, Tolerability, and Clinical Benefit of RPh201 in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease

NCT03462121 is registered in ClinicalTrials.gov with Regenera Pharma Ltd as lead sponsor.

NCT NCT03462121
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03462121 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 6-Month, Double-Blind, Phase 2 Study and 6-Month Open- Label Extension Evaluating the Safety, Tolerability, and Clinical Benefit of RPh201 in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease
Lead sponsor
Regenera Pharma Ltd
Phase
Phase 2
Overall status
Completed
Start date
March 1, 2018
Completion date
March 30, 2020
Enrollment
83 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

mild to moderate dementia due to alzheimer's disease, with or without coexisting cerebrovascular disease